Outcomes after Everolimus Eluting Coronary Stent Implantation in Latin American Women  by Ng, Vivian G. & Lansky, Alexandra J.
Ng & Lansky
Outcomes after Everolimus Eluting Stent in Latin American Women
Rev Bras Cardiol Invasiva. 
2012;20(3)
1
Outcomes after Everolimus Eluting Coronary Stent 
Implantation in Latin American Women
Vivian G. Ng1, Alexandra J. Lansky2
Editorial
Rev Br s Cardiol Invasiva. 
2012;20(3)
1 MD. Cardiology fellow. Yale University Medical Center. New Ha-
ven, CT, USA.
2 MD. Associate professor and director. Interventional Cardiology 
Research – Yale University Medical Center. New Haven, CT, USA.
Correspondence: Alexandra J. Lansky. Yale University Medical Center – 
PO Box 208017 – New Haven, CT, USA – 06520-8017
E-mail: alexandra.lansky@yale.edu
Received on: 8/8/2012 • Accepted on: 8/9/2012
Coronary artery disease (CAD) is the leading cause of death in men and women1, and drug eluting stents (DES) have become a mainstay of percuta-
neous coronary interventions. Increased attention is now 
being paid to outcome differences between different 
geographic regions and between genders. Prior studies 
have shown that Latin Americans have high rates of 
cardiovascular disease and may have worse outcomes 
compared to patients in other regions.2-4 Latin American 
women may represent a particularly high-risk patient 
population since female gender has also been implica ted 
as a risk factor for worse outcomes after percutaneous 
coronary interventions.5,6
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Prior studies have demonstrated the superior efficacy 
and safety of the XIENCETM V everolimus eluting stent 
(Abbott Vascular, Santa Clara, CA, USA) compared to 
first generation DES.7,8 The XIENCETM V SPIRIT Women 
Study was the first dedicated prospective multicenter 
registry of women with de novo CAD.9 Approximately 
10% of the study population in the SPIRIT Women 
re gistry was from Latin America allowing for a unique 
opportunity to evaluate outcomes of Latin American 
women compared to other women after receiving the 
XIENCETM V stent.
In this issue of the Revista Brasileira de Cardiolo ­
gia Invasiva, Grinfeld et al.10 report an analysis of the 
SPIRIT Women study specifically comparing outcomes 
of women in Latin America to women from other 
countries. Overall women from Latin America had 
higher rates of co-morbid disease including higher 
rates of hy pertension, prior myocardial infarction and 
family history of CAD. Furthermore, they had worse 
baseline angiographic characteristics such as smaller 
reference vessel diameters and longer lesion lengths. 
These high rates of known CAD risk factors in Latin 
American patients have been previously reported and 
have been implicated in the overall high CAD rates 
seen in this population.4,11,12 Hypertension, diabetes 
and prior myocardial infarction rates appeared to be 
higher in this study compared to prior studies in Latin 
American patients.11 This is not completely unexpected 
since women in general have higher rates of these tra-
ditional risk factors than men. This study’s all-female 
population has similar rates of comorbidities compared 
to other female populations included in clinical trials.13
Despite these differences in baseline characteris-
tics, this study found that Latin American women had 
similar rates of the primary composite endpoint (all 
cause death, myocardial infarction and target vessel 
revascularization) compared to non-Latin American wo-
men (10.1% vs. 12.1%; P = 0.58). Furthermore, 1-year 
mortality rates were low in both population subsets 
(0.7% in Latin American women vs. 1.6% in non-Latin 
American women). Rates of target vessel failure, death 
and myocardial infarction in this study are comparable 
to results seen in other real world studies.14 
This analysis offers encouraging data supporting 
the use of XIENCETM V in high-risk populations in-
cluding Latin American women. Unlike prior studies 
which showed outcome differences in Latin American 
patients compared to non-Latin American patients, this 
study demonstrated similar outcomes between Latin 
American and non-Latin American women treated with 
an everolimus eluting stent. This discrepancy may be 
related to differences in study inclusion criteria. Prior 
studies demonstrating worse outcomes in Latin Ame-
rican patients included patients presenting with acute 
coronary syndromes regardless of whether the patient 
was going to receive invasive management or not. In 
these studies, treatment discrepancies between Latin 
and North American countries were described and 
patients in Latin America were less likely to receive 
revascularization.4 Thus, the lesser invasive treatment 
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of patients in Latin America likely contributed to the 
overall worse outcomes seen in those studies.4 In 
contrast, the SPIRIT Women registry only included 
women who were receiving percutaneous coronary 
interventions therefore eliminating confounding inva-
sive versus conservative management differences that 
could have impacted outcomes. Thus, based on this 
small patient analysis, women in Latin America likely 
benefit from the same invasive treatments as women 
in other geographical regions.
The specific stent used in this study may have also 
contributed to the outcome similarity seen between 
geographic populations. In this study, Latin American 
women had higher rates of small vessels with long 
lesions, which are known to have worse outcomes 
com pared to patients with larger vessels.11,12 Different 
types of DES are not equivalent in treating small vessel 
disease13, and prior studies have demonstrated the effi-
cacy of the everolimus eluting stent in treating small 
vessel CAD compared to other stent types.11,14 The 
demonstrated beneficial outcomes of the XIENCETM V 
stent in small vessels and long lesions may have helped 
narrow outcome differences observed between Latin 
and non-Latin American women. Outcome comparisons 
between Latin American women and other women after 
treatment with stents that are less successful at treating 
small vessel disease has not been reported
This analysis of a real-world female population 
offers promising data for the treatment of Latin Ame-
rican women. In spite of higher rates of co-morbid 
conditions and high-risk angiographic features, Latin 
American women treated with the everolimus eluting 
stents for CAD have similar low rates of clinical out-
co mes compared to other women.
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